Physicochemical Properties
Molecular Formula | C12H16N4O |
Molecular Weight | 232.287 |
Exact Mass | 232.132 |
Elemental Analysis | C, 62.05; H, 6.94; N, 24.12; O, 6.89 |
CAS # | 1009734-33-1 |
PubChem CID | 24778294 |
Appearance | White to light yellow solid powder |
Density | 1.2±0.1 g/cm3 |
Boiling Point | 471.6±53.0 °C at 760 mmHg |
Flash Point | 239.0±30.9 °C |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.658 |
LogP | 2.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Heavy Atom Count | 17 |
Complexity | 266 |
Defined Atom Stereocenter Count | 0 |
SMILES | O(C1=CC=CC2C1=C(N)N=C(N)N=2)C(C)(C)C |
InChi Key | JQHKDYFLRJIBLX-UHFFFAOYSA-N |
InChi Code | InChI=1S/C12H16N4O/c1-12(2,3)17-8-6-4-5-7-9(8)10(13)16-11(14)15-7/h4-6H,1-3H3,(H4,13,14,15,16) |
Chemical Name | 5-(1,1-Dimethylethoxy)- 2,4-quinazolinediamine |
Synonyms | HZ-1157; HZ 1157; HZ1157. Dengue Virus Inhibitor II. |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | Numerous biological actions of HZ-1157 (4a) are known to exist, including dihydrofolate reductase inhibition, SMN2 promoter activation, and inhibition of protein lysine methyltransferase G9a[1][2]. |
Cell Assay |
Cell viability assay [2]. Cell Types: HZ-1157 (4a) is known to have a wide range of biological activities, such as protein lysine methyltransferase G9a inhibition, SMN2 promoter activation, dihydrofolate reductase inhibition, etc. Tested Concentrations: 0-10μmol/L. Incubation Duration: 72 hrs (hours). Experimental Results: Inhibited HCV infection in vitro, IC50 was 0.82 μmol/L. |
References |
[1]. Discovering Novel anti-HCV Compounds With Inhibitory Activities Toward HCV NS3/4A Protease. Acta Pharmacol Sin. 2014 Aug;35(8):1074-81. [2]. Discovery and Optimization of 2,4-diaminoquinazoline Derivatives as a New Class of Potent Dengue Virus Inhibitors. J Med Chem . 2012 Apr 12;55(7):3135-43. |
Solubility Data
Solubility (In Vitro) | DMSO : ~20 mg/mL (~86.10 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2 mg/mL (8.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2 mg/mL (8.61 mM)  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.3050 mL | 21.5248 mL | 43.0496 mL | |
5 mM | 0.8610 mL | 4.3050 mL | 8.6099 mL | |
10 mM | 0.4305 mL | 2.1525 mL | 4.3050 mL |